Catalent Pharma Solutions

Various impurities can infiltrate the container closure system in pharmaceutical manufacturing. Understanding nitrosamines, elemental impurities, extractables, and leachables can help ensure the safety of the final product.

Lipid-based formulations can improve the oral bioavailability of some molecules. However, a poor understanding of the technology and complexities limit their use.

It is essential to have access to the right tools and expertise to support process development for biologic therapies, from the clinical trial phase to commercialization.

Modern mathematical and computerized modelling tools can improve scale-up and efficiency of continuous manufacturing of oral solid dosage drugs.

A company focused on the treatment of advanced solid tumors, partnered with Catalent for the development, clinical trial supply and scale-up of a spray-drying program.

Discover how to use enteric polymer coatings effectively for controlled drug delivery in oral medications to enhance your drug formulations.

Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST

When developing a tablet or capsule formulation, three widely used technologies are often considered to produce solid dosage forms: direct compression, wet granulation and dry granulation (including roller compaction). This article discusses why roller compaction is a robust option.

A biotech company focused treatment of advanced solid tumors, partnered with Catalent for the development, clinical trial supply and scale-up of a spray-drying program.

The transition from early phase to late phase of a small molecule program plays a pivotal role in determining a program’s ultimate success. Early planning strategies can help minimize the burdens often faced in that transition. The implementation of modeling tools to analyze the relationships between material attributes, process parameters and product performance can provide an enhanced understanding of the drug product and improve manufacturing efficiency. In this executive summary, experts will demonstrate how Catalent’s (multivariate) modeling tools can help understand the relationship between material Critical Material Attributes (CMAs), unit operation Critical Process Parameters (CPPs) and their impact on the finished dosage. In addition, the experts will explain how these approaches can facilitate in the tech transfer of a program. Lastly, this executive summary includes an overview of Catalent’s oral solid dose turnkey solutions featuring advanced oral solid dosage (OSD) manufacturing technologies and expertise throughout an extensive global network.

OptiForm® Solution Suite is a fast, flexible, and fact-based screening platform, which works in combination with Catalent’s comprehensive bioavailability enhancing technology toolkit.

By adapting for each molecule’s unique characteristics and challenges, Catalent uses its expertise and a wide range of tools and technologies to create innovative dose forms that benefit patients.

Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market.

Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market.

Bioassays are critical for assessing potency and biological activity during biopharmaceutical activity, but they must be carefully designed to ensure reliability. Learn about new developments in cell-based bioassays and binding assays.

In today’s challenging environment, every clinical study is different and changes can occur during project development which require unique, responsive solutions. Catalent offers flexible services designed to keep studies moving.

#wpbut {border: 3px solid #245998; border-radius:40px; border-color: #245998; padding: 15px 30px; font-size:15px !important;} #wpbut:hover {background: #15355a; color: #fff !important; transition: .5s;}